PTD-DBM
A cell-penetrating peptide designed to reactivate Wnt/beta-catenin signaling in hair follicles by disrupting the CXXC5-Dishevelled interaction, studied for hair regrowth.
PTD-DBM is a synthetic peptide that fuses a protein transduction domain (PTD) for intracellular delivery with a Dishevelled-binding motif (DBM) derived from the CXXC5 protein. By competitively disrupting the CXXC5-Dishevelled interaction that normally suppresses Wnt/beta-catenin signaling, it aims to restore Wnt pathway activity in hair follicle stem cells and dermal papilla cells to promote follicle cycling and neogenesis in androgenetic alopecia. Evidence is preclinical only, based on cell-based and mouse studies; no published human clinical trials, pharmacokinetic data, or safety trials have been indexed.
Class
Synthetic cell-penetrating peptide (protein transduction domain fused to a Dishevelled-binding motif)
Routes
Topical, Intradermal
Category
Skin, Hair & Cosmetic
Researched benefits
What it's studied for
Hair regeneration
PTD-DBM is studied for its ability to stimulate hair regrowth by reactivating Wnt/beta-catenin signaling, a pathway central to hair follicle stem cell activation. Evidence to date is from preclinical mouse models of hair loss.
Hair follicle activation
By restoring Wnt activity in follicular dermal papilla cells, the peptide is proposed to drive follicles from rest into the active growth phase. This effect has been demonstrated in preclinical cell-based and animal studies.
Wnt pathway modulation
The peptide disrupts the CXXC5-Dishevelled interaction, preventing beta-catenin degradation and allowing its nuclear translocation to switch on Wnt target genes involved in follicle biology.
Follicle neogenesis
Reactivation of Wnt signaling is associated with the formation of new hair follicles (neogenesis) in preclinical work, positioning PTD-DBM as a candidate for androgenetic alopecia research.
Mechanism
How it works
PTD-DBM combines two functional elements: a protein transduction domain (PTD) that enables the peptide to cross cell membranes and reach intracellular targets, and a Dishevelled-binding motif (DBM) taken from the CXXC5 protein. CXXC5 is a negative feedback regulator of the Wnt pathway.
In hair follicles, CXXC5 normally binds Dishevelled to prevent beta-catenin from accumulating and translocating to the nucleus, thereby suppressing Wnt target gene expression. This checkpoint dampens the follicle's regenerative signaling, a factor implicated in androgenetic alopecia and DHT-driven hair loss.
The DBM portion of PTD-DBM competitively disrupts the CXXC5-Dishevelled interaction. By freeing Dishevelled, it prevents beta-catenin degradation and restores Wnt/beta-catenin pathway activity in follicular dermal papilla and stem cells, promoting follicle cycling and new follicle formation. This mechanism has been demonstrated to stimulate hair follicle activation in preclinical mouse models, though no human data characterize its safety, bioavailability, or efficacy.
Safety
Side effects & considerations
Contraindications & cautions
- Active or history of cancer
- Pregnancy or nursing
PTD-DBM is generally considered lower risk in research contexts, but no human safety data exist. Because it activates Wnt/beta-catenin signaling, a pathway implicated in cell proliferation, caution is advised for individuals with a cancer history. Individual response varies; review all contraindications and consult a qualified professional before use.
FAQ
PTD-DBM — common questions
What is PTD-DBM?
PTD-DBM is a synthetic peptide that combines a protein transduction domain (PTD) for cell penetration with a Dishevelled-binding motif (DBM) from the CXXC5 protein. It is engineered to disrupt the CXXC5-Dishevelled interaction that suppresses Wnt/beta-catenin signaling, aiming to reactivate the Wnt pathway in hair follicle stem cells to promote follicle cycling and hair regrowth in androgenetic alopecia.
What is PTD-DBM primarily studied for?
It is primarily studied for hair regeneration, hair follicle activation, Wnt pathway modulation, and follicle neogenesis.
How does PTD-DBM work?
CXXC5 normally binds Dishevelled to block beta-catenin from entering the nucleus, shutting down Wnt target genes. PTD-DBM competitively disrupts this interaction, restoring Wnt/beta-catenin activity in follicular dermal papilla cells, which is associated with hair follicle activation in preclinical models.
Is there human clinical evidence for PTD-DBM?
No. There are no published human clinical trials, pharmacokinetic studies, or Phase 1 safety data indexed for PTD-DBM. The available literature consists of preclinical cell-based and mouse studies of the CXXC5/Wnt/DHT axis in androgenetic alopecia.
What are the side effects and contraindications of PTD-DBM?
No human side-effect data exist. Reported contraindications and considerations include an active or prior cancer history and pregnancy or nursing. This is educational information only; consult a qualified healthcare professional before use.
How is PTD-DBM administered?
In research and cosmetic contexts it is applied topically or intradermally to the scalp, matching its intended site of action at the hair follicle.
What is the regulatory status of PTD-DBM?
PTD-DBM has not been evaluated by the FDA and has no approved indication in any jurisdiction. It is designated research-only.
